On 17 January 2018, orphan designation (EU/3/17/1962) was granted by the European Commission to MWB Consulting Ltd, United Kingdom, for humanised Fc-engineered monoclonal antibody against CD19 (also known as XmAb5871) for the treatment of IgG4-related disease.

The sponsorship was transferred to MWB Consulting S.A.R.L., France, in November 2018.

Key facts

Active substance
Humanised Fc-engineered monoclonal antibody against CD19
Disease / condition
Treatment of IgG4-related disease
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MWB Consulting S.A.R.L.
1 La Cour
50210 Belval
Tel: +33 9 79 60 26 31

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating